Home › Nasopharyngeal Carcinoma › Ohio › Cincinnati
Nasopharyngeal Carcinoma clinical trials in Cincinnati, OH
3 studies for Nasopharyngeal Carcinoma are looking for participants at sites in and around Cincinnati (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecruitingPhase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi away
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi away
Nasopharyngeal Carcinoma trials in other cities
- Atlanta, GA6 studies
- Houston, TX3 studies
- Pittsburgh, PA3 studies
- Richmond, VA3 studies
- Los Angeles, CA3 studies
- Milwaukee, WI3 studies
- Chicago, IL3 studies
- San Francisco, CA3 studies
- Washington, DC3 studies
- Charlotte, NC3 studies
- Oklahoma City, OK3 studies
Other studies in Cincinnati
- Non-Small Cell Lung Cancer35 studies
- Cancer (all types)27 studies
- Breast Cancer25 studies
- Heart Failure24 studies
- Colorectal Cancer21 studies
- Metastatic Cancer21 studies
- Acute Myeloid Leukemia20 studies
- Ovarian Cancer19 studies
- Obesity19 studies
- Lung Cancer19 studies
- Prostate Cancer18 studies
- Melanoma17 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.